Dalteparin reduced venous thromboembolic events without increased bleeding in acutely ill medical patients

March 2005
ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p40
Academic Journal
The article cites a study, which determines the efficacy and safety of dalteparin for prevention of venous thromboembolic events in acutely ill medical patients. 3706 patients were included for the study that had an acute medical condition requiring 4 days of hospitalization and had been immobilized for 3 days. Dalteparin reduced combined venous thromboembolism and sudden death more than placebo in acutely ill medical patients at 21 days and did not increase bleeding. The study was published in the 2004 issue of the journal "Circulation."


Related Articles

  • What are the best agents for preventing VTE in hospital patients?  // Journal of Family Practice;Oct2007, Vol. 56 Issue 10, p796 

    The article presents a meta-analysis which aims to determine which pharmacological agents are effective to prevent venous thromboembolism (VTE) in hospitalized medical patients. A literature search was performed to determine randomized trials that compared unfractionated heparin with control,...

  • Fondaparinux: Use in Thromboprophylaxis of Acute Medical Patients. Dhillon, Sohita; Plosker, Greg L. // Drugs & Aging;2008, Vol. 25 Issue 1, p81 

    Fondaparinux is a synthetic pentasaccharide that inhibits thrombin formation and thrombus development via selective antithrombin mediated inhibition of factor Xa. The complete bioavailability (100%) and elimination half-life of ≈17 hours allows once-daily administration of fondaparinux. In...

  • Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Takeshi Fuji; Satoru Fujita; Takahiro Ochi // International Orthopaedics;Aug2008, Vol. 32 Issue 4, p443 

    Abstract  Venous thromboembolism (VTE) is an important complication of major orthopaedic surgery of the lower limbs. Fondaparinux, a synthetic pentasaccharide and highly selective inhibitor of activated Factor Xa, is the first in a new class of antithrombotic agents. To determine the...

  • Extended prophylaxis with idraparinux prevented recurrence of venous thromboembolism but increased risk for bleeding.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p20 

    The article presents a study which examines the effectiveness of idraparinux in treating patients with venous thromboembolism (VTE) who have completed six months of anticoagulant therapy. In patients with VTE who had completed six months of anticoagulant therapy, study shows that idraparinux...

  • Low-dose warfarin prevents recurrent thromboembolism. Plum, Mary-Beth Fennell // Journal of Family Practice;Aug2003, Vol. 52 Issue 8, p588 

    The article discusses research on the use of low-dose warfarin to prevent recurrent venous thromboembolism. Low-dose warfarin does not increase the risk of major bleeding when used for secondary prophylaxis. This should follow after three to twelve months of full-intensity warfarin after the...

  • AVALIAÇÃO DO RISCO DE TROMBOEMBOLISMO VENOSO. FRANÇA, Ana; DE SOUSA, Joaquim Abreu; FELICÍSSIMO, Paulo; FERREIRA, Daniel // Acta Medica Portuguesa;SUP2011, Vol. 24 Issue S2, p575 

    Venous thromboembolism is a frequent clinical condition with high impact on both morbidity and mortality. Venous thromboembolism risk is particularly high in hospitalized patients as well as in oncologic patients, being a factor of poor prognosis for the oncologic disease. Several clinical...

  • EXTENDED ANTICOAGULATION FOR A FIRST EPISODE OF IDIOPATHIC VENOUS THROMBOEMBOLISM. Sparano, Nicole; English, Richard // Journal of Family Practice;Aug1999, Vol. 48 Issue 8, p579 

    The article presents information on a study that examined the effectiveness of extended anticoagulant therapy in decreasing the recurrence rate of idiopathic venous thromboembolism (VTE). The study included 162 patients with a first episode of idiopathic VTE who had completed three uninterrupted...

  • Anaemia drug raises clot risk.  // GP: General Practitioner;2/29/2008, p14 

    The article reports that treating anemia in cancer patients with erythropoiesis-stimulating agents (ESAs) can increase blood clot risk as stated in the U.S. research findings. According to the author, anemia in cancer is often treated with erythropoeitin and darbepoetin but there have been...

  • A Randomized Control Trial to Verify the Efficacy of Pre-Operative Intra Venous Tranexamic Acid in the Control of Tonsillectomy Bleeding. George, Ajay; Kumar, Ranjan; Kumar, Sanjay; Shetty, Sharankumar // Indian Journal of Otolaryngology & Head & Neck Surgery;Jan2011, Vol. 63 Issue 1, p20 

    Tonsillectomy is an age old surgery which is still very commonly done. Bleeding related to surgery is the major problem. This study is done to verify by randomized control trial the efficacy of preoperative intravenous tranexamic acid in the control of tonsillectomy bleeding. Hundred cases...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics